Literature DB >> 10029575

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

N Raje1, J Gong, D Chauhan, G Teoh, D Avigan, Z Wu, D Chen, S P Treon, I J Webb, D W Kufe, K C Anderson.   

Abstract

Multiple myeloma (MM) cells express idiotypic proteins and other tumor-associated antigens which make them ideal targets for novel immunotherapeutic approaches. However, recent reports show the presence of Kaposi's sarcoma herpesvirus (KSHV) gene sequences in bone marrow dendritic cells (BMDCs) in MM, raising concerns regarding their antigen-presenting cell (APC) function. In the present study, we sought to identify the ideal source of DCs from MM patients for use in vaccination approaches. We compared the relative frequency, phenotype, and function of BMDCs or peripheral blood dendritic cells (PBDCs) from MM patients versus normal donors. DCs were derived by culture of mononuclear cells in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. The yield as well as the pattern and intensity of Ag (HLA-DR, CD40, CD54, CD80, and CD86) expression were equivalent on DCs from BM or PB of MM patients versus normal donors. Comparison of PBDCs versus BMDCs showed higher surface expression of HLA-DR (P =.01), CD86 (P =. 0003), and CD14 (P =.04) on PBDCs. APC function, assessed using an allogeneic mixed lymphocyte reaction (MLR), demonstrated equivalent T-cell proliferation triggered by MM versus normal DCs. Moreover, no differences in APC function were noted in BMDCs compared with PBDCs. Polymerase chain reaction (PCR) analysis of genomic DNA from both MM patient and normal donor DCs for the 233-bp KSHV gene sequence (KS330233) was negative, but nested PCR to yield a final product of 186 bp internal to KS330233 was positive in 16 of 18 (88.8%) MM BMDCs, 3 of 8 (37.5%) normal BMDCs, 1 of 5 (20%) MM PBDCs, and 2 of 6 (33.3%) normal donor PBDCs. Sequencing of 4 MM patient PCR products showed 96% to 98% homology to the published KSHV gene sequence, with patient specific mutations ruling out PCR artifacts or contamination. In addition, KHSV-specific viral cyclin D (open reading frame [ORF] 72) was amplified in 2 of 5 MM BMDCs, with sequencing of the ORF 72 amplicon revealing 91% and 92% homology to the KSHV viral cyclin D sequence. These sequences again demonstrated patient specific mutations, ruling out contamination. Therefore, our studies show that PB appears to be the preferred source of DCs for use in vaccination strategies due to the ready accessibility and phenotypic profile of PBDCs, as well as the comparable APC function and lower detection rate of KSHV gene sequences compared with BMDCs. Whether active KSHV infection is present and important in the pathophysiology of MM remains unclear; however, our study shows that MMDCs remain functional despite the detection of KSHV gene sequences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029575

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.

Authors:  Davorka Messmer; Gloria Telusma; Tarun Wasil; Bradley T Messmer; Steven Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

2.  Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display.

Authors:  Marina Kovaleva; Ingo Bussmeyer; Björn Rabe; Joachim Grötzinger; Enge Sudarman; Jutta Eichler; Udo Conrad; Stefan Rose-John; Jürgen Scheller
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.

Authors:  Patrizia Leone; Simona Berardi; Maria Antonia Frassanito; Roberto Ria; Valli De Re; Sebastiano Cicco; Stefano Battaglia; Paolo Ditonno; Franco Dammacco; Angelo Vacca; Vito Racanelli
Journal:  Blood       Date:  2015-07-16       Impact factor: 22.113

Review 4.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

Review 5.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma.

Authors:  Baptiste Lamarthée; Frédéric de Vassoigne; Florent Malard; Nicolas Stocker; Inès Boussen; Clémence Médiavilla; Ruoping Tang; Fanny Fava; Laurent Garderet; Zora Marjanovic; Eolia Brissot; Mohamad Mohty; Béatrice Gaugler
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

Review 7.  Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases.

Authors:  Dharam V Ablashi; Louise G Chatlynne; James E Whitman; Ethel Cesarman
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma.

Authors:  M K Brimnes; I M Svane; H E Johnsen
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 9.  Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.

Authors:  Tomas Büchler; Roman Hajek
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 10.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.